Aprea Therapeutics files updated corporate slide deck; no material new data disclosed

Aprea Therapeutics, Inc.

Filed updated corporate presentation dated September 2025 under Item 8.01.
Presentation titled 'Precision Oncology Through Synthetic Lethality' continues DDR inhibition focus.
No specific financial, clinical, or pipeline milestones were evident from the excerpt provided.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.